Ignite Creation Date:
2024-05-06 @ 5:24 PM
Last Modification Date:
2024-10-26 @ 2:28 PM
Study NCT ID:
NCT05291052
Status:
UNKNOWN
Last Update Posted:
2022-03-22
First Post:
2022-03-14
Brief Title:
Tisleizumab Combined With Lenvatinib and XELOX Regimen Oxaliplatin Combined With Capecitabine in the First-line Treatment of Advanced and Unresectable Biliary Tract Tumors
Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Organization:
The First Affiliated Hospital with Nanjing Medical University
Organization Data
Organization:
The First Affiliated Hospital with Nanjing Medical University
Class:
OTHER
Study ID:
Tis-BTC-001
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None